·Î±×ÀÎ Àüü´º½º¿ÀÇǴϾðEnglishÆÊ ¾ÆÄ«µ¥¹ÌÆʽºÅ¸Å¬·´TVÆʵµ¶ó¸®Äí¸£Æ®DPºÎµ¿»êÀλ絿Á¤Event & Çмú¼¼¹Ì³ªµ¶ÀÚÁ¦º¸
°Ë»ö ä¿ëÁ¤º¸ ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø ±â»çÀÔ·Â : 23.03.21 09:40:34 0 °¡ ÇÃÄ£Ãß°¡ [µ¥Àϸ®ÆÊ=±èÁöÀº ±âÀÚ] ¾àÇÐÁ¤º¸¿ø(¿øÀå ±èÇöÅÂ)Àº 21ÀÏ ¿Â¶óÀÎ ÇмúÁ¤º¸Áö ¡®Æʸ®ºä¡¯¿¡¼ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ°¡ Á¦°øÇÏ´Â ¾à¹° À¯¹ß¼º Áúȯ(drug-induced disease) Á¤º¸ ½Ã¸®Áî ùȸ·Î ¡®Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾à¹° ¾ÈÀü¼º Á¤º¸¡¯¸¦ °ø°³Çß´Ù°í ¹àÇû´Ù. À̹ø Æʸ®ºä¿¡¼´Â °úÇÐÀû ±Ù°Å ¹®ÇåÀ» Åä´ë·Î Ç÷Áß ÁöÁú ¼öÄ¡¸¦ ¾ÇȽÃÅ°°Å³ª Ç÷°ü¿°À» À¯¹ßÇÏ´Â ´Ù¾çÇÑ ¾à¹°°ú Ç÷°ü °ü·Ã ºÎÀÛ¿ë ¹ß»ý ±âÀü µîÀÌ ¼Ò°³µÆ´Ù. ¶ÇÇÑ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ¿¡ º¸°íµÈ °ü·Ã »ç·Ê ºÐ¼® °á°úµµ Æ÷ÇԵŠ¾à»çµéÀÌ ½ÇÁ¦ ÀÓ»ó ¾÷¹«¿¡¼ Âü°íÇÒ ¼ö ÀÖµµ·Ï Çß´Ù´Â°Ô ¾àÁ¤¿ø ¼³¸íÀÌ´Ù. À̹ø Æʸ®ºä¿¡¼ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ´Â ¡°Ç÷Áß ÁöÁú ¼öÄ¡ÀÇ ¾ÇÈ´Â ½ÉÇ÷°ü Áúȯ À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î °ü·Ã ¾à¹°À» º¹¿ëÇϴ ȯÀÚ Áß ½ÉÇ÷°ü Áúȯ À§ÇèÀÌ ³ôÀº ȯÀÚÀÇ °æ¿ì ƯÈ÷ ²ÙÁØÇÑ ÁöÁú ¼öÄ¡ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÏ´Ù¡±°í °Á¶Çß´Ù. ¼¾ÅÍ´Â ¶Ç ¡°¾à¹° À¯¹ß¼º Ç÷°ü¿°Àº º´ÀÎÀÌ ¸íÈ®ÇÏÁö ¾Ê°í ºñƯÀÌÀûÀÎ ´Ù¾çÇÑ ÀÓ»óÁõ»óÀ» º¸Àδ١±¸ç ¡°Ç÷°ü¿°À» À¯¹ßÇÒ ¼ö ÀÖ´Â ¾à¹° ¹× Áõ»ó¿¡ ´ëÇØ ÀÎÁöÇÏ°í ¹ß»ý ½Ã ºü¸£°Ô ¾à¹° º¹¿ëÀ» Áß´ÜÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù¡±°í ¼³¸íÇß´Ù. ÇÑÆí À̹ø Æʸ®ºä´Â ¾àÇÐÁ¤º¸¿ø ȨÆäÀÌÁö(https://www.health.kr/researchInfo/pharmreview.asp) ¶Ç´Â ¾à±¹¼ºñ½ºÇ÷§Æû(PharmIT3000, PM+20)¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ´Ù. X AD Â¥¸Ô´Â Àº±³»ê Ãâ½Ã! À̺¥Æ®Âü¿© ¡æ ±èÁöÀº ±âÀÚ(bob83@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç Sr. Regulatory Affairs Specialist (18 months contract) ¹Ù·Î°¡±â ´õÇö´ë ¼¿ï ÇÍŸ¹Î ¾à±¹ ÆÄÆ® ¾à»ç ä¿ë ¹Ù·Î°¡±â ÇØÅÂhtb ÀÍ»ê°øÀå °ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â PMS Lead (Fixed-term) ¹Ù·Î°¡±â Junior Marketing Manager ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ PM °æ·Â(2³â ÀÌ»ó) ä¿ë ¹Ù·Î°¡±â Medical Science Liaison (Oncology) / Head of Market Access & External Affairs / MR(¿µ¾÷ºÎ) ä¿ë ¹Ù·Î°¡±â ¼¿Æ®¸®¿Â 2025³â 1Â÷ ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â Ç°Áú±×·ìÀå(ÀÌ»ç±Þ), °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â °³¹ß±âȹÆÀ BD °æ·Â(7³â ÀÌ»ó)ä¿ë ¹Ù·Î°¡±â Á¶¾ÆÁ¦¾à Ç°Áú°ü¸®¾à»ç °æ·Â ä¿ë ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Sr. MSL Associate ä¿ë(Á¤±ÔÁ÷) ¹Ù·Î°¡±â Senior Regulatory Science Specialist(1Yr) ¹Ù·Î°¡±â (Sr.) Local Research Specialist ¹Ù·Î°¡±â Æĸ¶¿¡¼¾½Ã¾ÆÄÚ¸®¾Æ MSL ½Å±Ô ä¿ë ¹Ù·Î°¡±â Á¦¾à¾à»çä¿ë ¹Ù·Î°¡±â ¸¶ÄÉÆà ¾à»ç, Àü¹®¿¬±¸¿ä¿ø ¸ðÁý ¹Ù·Î°¡±â [À¯¸í¿Ü±¹°èÁ¦¾à»ç] ½ÅÀÔ¾à»ç & °æ·Â MSL µî ´Ù¼ö ¹Ù·Î°¡±â ¢ß¼¿Æ®¸®¿ÂÁ¦¾à ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â (ÀüºÏ(ÀüÁÖ °ÅÁÖ)) ¿µ¾÷ºÎ ½ÅÀÔ/°æ·ÂÁ÷(ÁÖÀÓ~´ë¸®±Þ) ¸ðÁý ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Medical Scientific Affair ä¿ë(À°¾ÆÈÞÁ÷´ëü_±â°£Á¦) ¹Ù·Î°¡±â Medical Representative (Á¾º´ ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â QC, QA, Medical Affairs, MR(º´¿ø¿µ¾÷) ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ¿ø(Á¤±ÔÁ÷), RA/QAÆÀ¿ø,PVÆÀ¿ø(°è¾àÁ÷) ä¿ë ¹Ù·Î°¡±â Medical Representative (Ŭ¸®´Ð ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø ±â»çÀÔ·Â : 23.03.21 09:40:34 0 °¡ ÇÃÄ£Ãß°¡ [µ¥Àϸ®ÆÊ=±èÁöÀº ±âÀÚ] ¾àÇÐÁ¤º¸¿ø(¿øÀå ±èÇöÅÂ)Àº 21ÀÏ ¿Â¶óÀÎ ÇмúÁ¤º¸Áö ¡®Æʸ®ºä¡¯¿¡¼ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ°¡ Á¦°øÇÏ´Â ¾à¹° À¯¹ß¼º Áúȯ(drug-induced disease) Á¤º¸ ½Ã¸®Áî ùȸ·Î ¡®Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾à¹° ¾ÈÀü¼º Á¤º¸¡¯¸¦ °ø°³Çß´Ù°í ¹àÇû´Ù. À̹ø Æʸ®ºä¿¡¼´Â °úÇÐÀû ±Ù°Å ¹®ÇåÀ» Åä´ë·Î Ç÷Áß ÁöÁú ¼öÄ¡¸¦ ¾ÇȽÃÅ°°Å³ª Ç÷°ü¿°À» À¯¹ßÇÏ´Â ´Ù¾çÇÑ ¾à¹°°ú Ç÷°ü °ü·Ã ºÎÀÛ¿ë ¹ß»ý ±âÀü µîÀÌ ¼Ò°³µÆ´Ù. ¶ÇÇÑ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ¿¡ º¸°íµÈ °ü·Ã »ç·Ê ºÐ¼® °á°úµµ Æ÷ÇԵŠ¾à»çµéÀÌ ½ÇÁ¦ ÀÓ»ó ¾÷¹«¿¡¼ Âü°íÇÒ ¼ö ÀÖµµ·Ï Çß´Ù´Â°Ô ¾àÁ¤¿ø ¼³¸íÀÌ´Ù. À̹ø Æʸ®ºä¿¡¼ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ´Â ¡°Ç÷Áß ÁöÁú ¼öÄ¡ÀÇ ¾ÇÈ´Â ½ÉÇ÷°ü Áúȯ À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î °ü·Ã ¾à¹°À» º¹¿ëÇϴ ȯÀÚ Áß ½ÉÇ÷°ü Áúȯ À§ÇèÀÌ ³ôÀº ȯÀÚÀÇ °æ¿ì ƯÈ÷ ²ÙÁØÇÑ ÁöÁú ¼öÄ¡ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÏ´Ù¡±°í °Á¶Çß´Ù. ¼¾ÅÍ´Â ¶Ç ¡°¾à¹° À¯¹ß¼º Ç÷°ü¿°Àº º´ÀÎÀÌ ¸íÈ®ÇÏÁö ¾Ê°í ºñƯÀÌÀûÀÎ ´Ù¾çÇÑ ÀÓ»óÁõ»óÀ» º¸Àδ١±¸ç ¡°Ç÷°ü¿°À» À¯¹ßÇÒ ¼ö ÀÖ´Â ¾à¹° ¹× Áõ»ó¿¡ ´ëÇØ ÀÎÁöÇÏ°í ¹ß»ý ½Ã ºü¸£°Ô ¾à¹° º¹¿ëÀ» Áß´ÜÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù¡±°í ¼³¸íÇß´Ù. ÇÑÆí À̹ø Æʸ®ºä´Â ¾àÇÐÁ¤º¸¿ø ȨÆäÀÌÁö(https://www.health.kr/researchInfo/pharmreview.asp) ¶Ç´Â ¾à±¹¼ºñ½ºÇ÷§Æû(PharmIT3000, PM+20)¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ´Ù. X AD Â¥¸Ô´Â Àº±³»ê Ãâ½Ã! À̺¥Æ®Âü¿© ¡æ ±èÁöÀº ±âÀÚ(bob83@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç Sr. Regulatory Affairs Specialist (18 months contract) ¹Ù·Î°¡±â ´õÇö´ë ¼¿ï ÇÍŸ¹Î ¾à±¹ ÆÄÆ® ¾à»ç ä¿ë ¹Ù·Î°¡±â ÇØÅÂhtb ÀÍ»ê°øÀå °ü¸®¾à»ç ä¿ë ¹Ù·Î°¡±â PMS Lead (Fixed-term) ¹Ù·Î°¡±â Junior Marketing Manager ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ PM °æ·Â(2³â ÀÌ»ó) ä¿ë ¹Ù·Î°¡±â Medical Science Liaison (Oncology) / Head of Market Access & External Affairs / MR(¿µ¾÷ºÎ) ä¿ë ¹Ù·Î°¡±â ¼¿Æ®¸®¿Â 2025³â 1Â÷ ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â Ç°Áú±×·ìÀå(ÀÌ»ç±Þ), °ü¸®¾à»ç ¸ðÁý ¹Ù·Î°¡±â °³¹ß±âȹÆÀ BD °æ·Â(7³â ÀÌ»ó)ä¿ë ¹Ù·Î°¡±â Á¶¾ÆÁ¦¾à Ç°Áú°ü¸®¾à»ç °æ·Â ä¿ë ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Sr. MSL Associate ä¿ë(Á¤±ÔÁ÷) ¹Ù·Î°¡±â Senior Regulatory Science Specialist(1Yr) ¹Ù·Î°¡±â (Sr.) Local Research Specialist ¹Ù·Î°¡±â Æĸ¶¿¡¼¾½Ã¾ÆÄÚ¸®¾Æ MSL ½Å±Ô ä¿ë ¹Ù·Î°¡±â Á¦¾à¾à»çä¿ë ¹Ù·Î°¡±â ¸¶ÄÉÆà ¾à»ç, Àü¹®¿¬±¸¿ä¿ø ¸ðÁý ¹Ù·Î°¡±â [À¯¸í¿Ü±¹°èÁ¦¾à»ç] ½ÅÀÔ¾à»ç & °æ·Â MSL µî ´Ù¼ö ¹Ù·Î°¡±â ¢ß¼¿Æ®¸®¿ÂÁ¦¾à ½ÅÀÔ/°æ·Â ¼ö½Ãä¿ë ¹Ù·Î°¡±â (ÀüºÏ(ÀüÁÖ °ÅÁÖ)) ¿µ¾÷ºÎ ½ÅÀÔ/°æ·ÂÁ÷(ÁÖÀÓ~´ë¸®±Þ) ¸ðÁý ¹Ù·Î°¡±â Çѱ¹¿¡ÀÚÀÌ Medical Scientific Affair ä¿ë(À°¾ÆÈÞÁ÷´ëü_±â°£Á¦) ¹Ù·Î°¡±â Medical Representative (Á¾º´ ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â QC, QA, Medical Affairs, MR(º´¿ø¿µ¾÷) ä¿ë ¹Ù·Î°¡±â ÀÓ»óÆÀ¿ø(Á¤±ÔÁ÷), RA/QAÆÀ¿ø,PVÆÀ¿ø(°è¾àÁ÷) ä¿ë ¹Ù·Î°¡±â Medical Representative (Ŭ¸®´Ð ¿µ¾÷ - °è¾àÁ÷) ¹Ù·Î°¡±â 0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö
ä¿ëÁ¤º¸ ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø ±â»çÀÔ·Â : 23.03.21 09:40:34 0 °¡ ÇÃÄ£Ãß°¡ [µ¥Àϸ®ÆÊ=±èÁöÀº ±âÀÚ] ¾àÇÐÁ¤º¸¿ø(¿øÀå ±èÇöÅÂ)Àº 21ÀÏ ¿Â¶óÀÎ ÇмúÁ¤º¸Áö ¡®Æʸ®ºä¡¯¿¡¼ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ°¡ Á¦°øÇÏ´Â ¾à¹° À¯¹ß¼º Áúȯ(drug-induced disease) Á¤º¸ ½Ã¸®Áî ùȸ·Î ¡®Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾à¹° ¾ÈÀü¼º Á¤º¸¡¯¸¦ °ø°³Çß´Ù°í ¹àÇû´Ù. À̹ø Æʸ®ºä¿¡¼´Â °úÇÐÀû ±Ù°Å ¹®ÇåÀ» Åä´ë·Î Ç÷Áß ÁöÁú ¼öÄ¡¸¦ ¾ÇȽÃÅ°°Å³ª Ç÷°ü¿°À» À¯¹ßÇÏ´Â ´Ù¾çÇÑ ¾à¹°°ú Ç÷°ü °ü·Ã ºÎÀÛ¿ë ¹ß»ý ±âÀü µîÀÌ ¼Ò°³µÆ´Ù. ¶ÇÇÑ ´ëÇѾà»çȸ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ¿¡ º¸°íµÈ °ü·Ã »ç·Ê ºÐ¼® °á°úµµ Æ÷ÇԵŠ¾à»çµéÀÌ ½ÇÁ¦ ÀÓ»ó ¾÷¹«¿¡¼ Âü°íÇÒ ¼ö ÀÖµµ·Ï Çß´Ù´Â°Ô ¾àÁ¤¿ø ¼³¸íÀÌ´Ù. À̹ø Æʸ®ºä¿¡¼ Áö¿ªÀǾàÇ°¾ÈÀü¼¾ÅÍ´Â ¡°Ç÷Áß ÁöÁú ¼öÄ¡ÀÇ ¾ÇÈ´Â ½ÉÇ÷°ü Áúȯ À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖÀ¸¹Ç·Î °ü·Ã ¾à¹°À» º¹¿ëÇϴ ȯÀÚ Áß ½ÉÇ÷°ü Áúȯ À§ÇèÀÌ ³ôÀº ȯÀÚÀÇ °æ¿ì ƯÈ÷ ²ÙÁØÇÑ ÁöÁú ¼öÄ¡ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÏ´Ù¡±°í °Á¶Çß´Ù. ¼¾ÅÍ´Â ¶Ç ¡°¾à¹° À¯¹ß¼º Ç÷°ü¿°Àº º´ÀÎÀÌ ¸íÈ®ÇÏÁö ¾Ê°í ºñƯÀÌÀûÀÎ ´Ù¾çÇÑ ÀÓ»óÁõ»óÀ» º¸Àδ١±¸ç ¡°Ç÷°ü¿°À» À¯¹ßÇÒ ¼ö ÀÖ´Â ¾à¹° ¹× Áõ»ó¿¡ ´ëÇØ ÀÎÁöÇÏ°í ¹ß»ý ½Ã ºü¸£°Ô ¾à¹° º¹¿ëÀ» Áß´ÜÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù¡±°í ¼³¸íÇß´Ù. ÇÑÆí À̹ø Æʸ®ºä´Â ¾àÇÐÁ¤º¸¿ø ȨÆäÀÌÁö(https://www.health.kr/researchInfo/pharmreview.asp) ¶Ç´Â ¾à±¹¼ºñ½ºÇ÷§Æû(PharmIT3000, PM+20)¿¡¼ È®ÀÎÇÒ ¼ö ÀÖ´Ù. X AD Â¥¸Ô´Â Àº±³»ê Ãâ½Ã! À̺¥Æ®Âü¿© ¡æ ±èÁöÀº ±âÀÚ(bob83@dailypharm.com) ±ÛÀÚÅ©±â ¼³Á¤ °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç °¡³ª´Ù¶ó¸¶¹Ù»ç
0/300 ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸ Ãë±Þ¹æħ | ¹ýÀû°íÁö Copyright ¨Ï Dailypharm 1999-2025,All rights reserved. ¸ÞÀϺ¸³»±â ±â»çÁ¦¸ñ : ¾àÁ¤¿ø, Æʸ®ºä¼ ¾à¹° À¯¹ß¼º Ç÷°ü Áúȯ Á¤º¸ Á¦°ø URLº¹»ç ¸ÞÀÏ Æ®À§ÅÍ ÆäÀ̽ººÏ Ä«Ä«¿À½ºÅ丮 Ä«Ä«¿ÀÅå ¹êµå ³×À̹ö